Exploring the Relationship Between Efpeglenatide Dose and Cardiovascular Outcomes in Type 2 Diabetes: Insights From the AMPLITUDE-O Trial
CONCLUSIONS: The graded salutary relationship between efpeglenatide dose and cardiovascular outcomes suggests that titrating efpeglenatide and potentially other glucagon-like peptide-1 receptor agonists to high doses may maximize their cardiovascular and renal benefits.REGISTRATION: URL: https://www.CLINICALTRIALS: gov; Unique identifier: NCT03496298.PMID:36802715 | DOI:10.1161/CIRCULATIONAHA.122.063716
Source: Circulation - Category: Cardiology Authors: Hertzel C Gerstein Zhuoru Li Chinthanie Ramasundarahettige Seungjae Baek Kelley R H Branch Stefano Del Prato Carolyn S P Lam Renato D Lopes Richard Pratley Julio Rosenstock Naveed Sattar Source Type: research
More News: Cardiology | Cardiovascular | Diabetes | Diabetes Type 2 | Endocrinology | Heart | Heart Attack | Heart Failure | Renal Failure | Statistics | Stroke | Urology & Nephrology